Direkt zum Inhalt
Merck

89434

Supelco

Ceftriaxon Dinatriumsalz Hemi(heptahydrat)

analytical standard

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C18H16N8Na2O7S3 · 3.5H2O
CAS-Nummer:
Molekulargewicht:
661.60
EG-Nummer:
MDL-Nummer:
UNSPSC-Code:
41116107
PubChem Substanz-ID:
NACRES:
NA.24

Qualität

analytical standard

Qualitätsniveau

Assay

≥90% (HPLC)

Haltbarkeit

limited shelf life, expiry date on the label

Methode(n)

HPLC: suitable
gas chromatography (GC): suitable

Verunreinigungen

~10% water

Anwendung(en)

clinical testing

Format

neat

Lagertemp.

2-8°C

SMILES String

O.O.O.O.O.O.O.[Na+].[Na+].CO\N=C(/C(=O)N[C@H]1C2SCC(CSC3=NC(=O)C(=O)N([Na])N3C)=C(N2C1=O)C([O-])=O)c4csc(N)n4.CO\N=C(/C(=O)N[C@H]5C6SCC(CSC7=NC(=O)C(=O)N([Na])N7C)=C(N6C5=O)C([O-])=O)c8csc(N)n8

InChI

1S/2C18H18N8O7S3.4Na.7H2O/c2*1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7;;;;;;;;;;;/h2*5,9,15H,3-4H2,1-2H3,(H5,19,20,21,23,27,29,31,32);;;;;7*1H2/q;;4*+1;;;;;;;/p-4/b2*24-8-;;;;;;;;;;;/t2*9-,15-;;;;;;;;;;;/m11.........../s1

InChIKey

PMRZKYOXTPBIQF-MAODNAKNSA-J

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

Chemical structure: ß-lactam

Anwendung

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Piktogramme

Health hazardExclamation mark

Signalwort

Danger

Gefahreneinstufungen

Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

Zielorgane

Respiratory system

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 1

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Choose from one of the most recent versions:

Analysenzertifikate (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Emphysematous pyelitis.
Kendall Luyt et al.
The Journal of pediatrics, 166(1), 201-201 (2014-10-01)
Ning Li et al.
Pediatrics, 133(4), e917-e922 (2014-03-26)
Our aim was to evaluate the clinical profile, treatment, and outcome of ceftriaxone-associated postrenal acute renal failure (PARF) in children. We retrospectively studied 31 consecutive cases from 2003 to 2012 for PARF after ceftriaxone treatment. There was no past history
Yi Yao et al.
Pharmacoepidemiology and drug safety, 21(11), 1197-1201 (2012-07-05)
The incidence of adverse reactions to ceftriaxone, which is widely used in China, has gradually increased, with an associated increase in patient fatality. An analysis of the reported data from articles published in China highlights the importance and extent of
Anthony R Flores et al.
The Journal of infectious diseases, 209(10), 1520-1523 (2013-12-07)
Invasive group A streptococcal (GAS) strains often have genetic differences compared to GAS strains from nonsterile sites. Invasive, "hypervirulent" GAS strains can arise from a noninvasive progenitor following subcutaneous inoculation in mice, but such emergence has been rarely characterized in
Dafydd Loughran et al.
Journal of clinical pathology, 67(5), 445-448 (2014-01-25)
This case report details the second described case of Whipple's disease-related thrombocytopenia in the medical literature. Whipple's disease is a rare multisystem infection caused by the actinomycete Tropheryma whipplei, first described by George Whipple in 1907. The key clinical manifestations

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.